Items Tagged ‘ABVD’

March 1, 2018

Addition of the Precision Cancer Medicine Adcetris Reduces the Risk of Treatment Failure in Advanced Hodgkin Lymphoma

By

CancerConnect News: Patients with advanced Hodgkin lymphoma (HL) who were treated with a multi-drug regimen that included the precision cancer medicine Adcetris (brentuximab vedotin) had a 23-percent reduction in the risk of disease progression, death, or the need for additional therapy, compared with patients who received the standard treatment for advanced HL.1 Hodgkin’s lymphoma is […]

View full entry

Tags: ABVD, adcetris, brentuximab, hodgkin lymphoma, Hodgkin's Lymphoma, News, Precision Cancer Medicine, vedotin